Previous 10 | Next 10 |
Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48...
BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors PR Newswire PALO ALTO, Calif. , Aug. 18, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commerci...
Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48 s...
BridgeBio Pharma (NASDAQ:BBIO): Q2 GAAP EPS of -$0.66 beats by $0.31. Revenue of $54.02M beats by $29.09M. Press Release For further details see: BridgeBio Pharma EPS beats by $0.31, beats on revenue
BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update --Received U.S. Food and Drug Administration (FDA) approval for TRUSELTIQ™ (infigratinib) under the accelerated approval program for patients with cholangiocarcinoma (CCA) --Recei...
AAWW,ABMD,ACIW,ADNT,AES,AHCO,AMRN,AMRS,APTV,ARW,ATH,BBIO,BCE,BDX,BEP,BERY,BIP,BKI,BLDR,BLL,BV,CAH,CARS,CCOI,CHH,CI,CNP,COMM,CQP,DDOG,DIN,DLX,DUK,ECOM,ECVT,EPAM,EPC,EVRG,FOCS,FOUR,FVRR,GCP,GIL,GOGO,GOLF,GRA,GTN,HBI,HII,HIMX,HL,IBP,IDCC,INSM,IRM,IRWD,ITRI,K,LNG,LXP,MMS,MRNA,MUR,NFE,NICE,NJR,NOM...
Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe; now holds 4...
BridgeBio Pharma (BBIO) announces a non-exclusive, co-funded clinical collaboration with Bristol Myers Squibb (BMY) to evaluate the combination of BBP-398 and Opdivo in patients with advanced solid tumors with KRAS mutations.The collaboration will also include the initiation of a Phase 1/2 st...
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations - First clinical combination study set to evaluate safety ...
Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holding...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...